Eli Lilly and Weight-Loss Pharma Now 20% of Irish Exports

In a landmark economic shift, the booming weight-loss pharmaceutical industry, led by Eli Lilly, now accounts for 20% of Irish goods exports. A new report reveals that pharma exports from Ireland reached €139bn in 2025, representing 53% of all goods exports—the highest on record. This surge is primarily fueled by key ingredients for GLP-1 drugs like semaglutide (used in Novo Nordisk's Ozempic and Wegovy) and tirzepatide (used in Eli Lilly's Mounjaro and Zepbound), highlighting Ireland's pivotal role in global metabolic health manufacturing.

Record-Breaking Growth in Irish Pharmaceutical Exports

The report, compiled by Goodbody chief economist Dermot O'Leary and titled The Pharmaceutical Sector In Ireland - A Health Check On Strengths, Risks, And Economic Impact, details how Irish exports of hormones and their derivatives skyrocketed from €14bn in 2024 to €51bn in 2025. This explosive growth underscores the demand for GLP-1 receptor agonists, medications originally developed for type 2 diabetes but now widely used for weight management and metabolic health.

GLP-1 drugs mimic the glucagon-like peptide-1 hormone, which regulates blood sugar, slows gastric emptying, and reduces appetite. Their efficacy in promoting significant weight loss—often 15-20% of body weight—has transformed obesity treatment, driving unprecedented manufacturing needs. Ireland's expertise in high-quality API (active pharmaceutical ingredient) production positions it as a key supplier in this supply chain.

Why This Matters for Metabolic Health Patients

For patients managing obesity, type 2 diabetes, or related conditions, this export boom signals increased global supply stability. However, access challenges persist. Discussing GLP-1 options like tirzepatide with your healthcare provider is crucial, especially considering factors like BMI, comorbidities, and potential side effects such as nausea or gastrointestinal issues. Tools like Shotlee can help track symptoms and medication adherence during therapy.

Eli Lilly's Expanding Footprint: Ireland to Indiana

The growth and success of Eli Lilly's weight-loss drugs is increasingly pronounced. The Goodbody report notes that almost 40% of all Irish pharmaceutical exports to the US in 2024 were destined for Indiana, home to one of the world's largest GLP-1 manufacturers—Eli Lilly. The company maintains a strong presence in Ireland with two major manufacturing facilities: one in Kinsale, Co. Cork, and another in Limerick.

Lilly's Kinsale site at Dunderrow already employs over 1,300 people. In a bold expansion, Eli Lilly has committed to investing a further $9bn in pharmaceutical manufacturing in Lebanon, Indiana—specifically focused on producing its GLP-1 drugs (Mounjaro & Zepbound) and their key API, tirzepatide.

Comparing Eli Lilly's Tirzepatide to Competitors

Tirzepatide, a dual GLP-1/GIP agonist, offers superior weight loss results compared to semaglutide in clinical trials, with average reductions up to 22%. While Novo Nordisk dominates with semaglutide-based products, Eli Lilly's innovations are closing the gap, supported by Ireland's manufacturing prowess. This competition benefits patients through potential price pressures and broader availability.

Lilly's Next Frontier: The Oral Obesity Drug Orforglipron

The take-up of GLP-1 drugs in the US is growing rapidly. This week, Eli Lilly chief financial officer Lucas Montarce announced the company is preparing to launch its new oral obesity drug, orforglipron, in the United States once approved by the US Food and Drug Administration. "Expect to see potentially that product coming into the market as early as Q2," Mr. Montarce said at the TD Cowen healthcare conference.

Lilly has $1.5bn (€1.29bn) worth of pre-launch inventory of the pill, with full commercial distribution in the US ready, according to Reuters. Orforglipron represents a convenient needle-free alternative, potentially expanding access for patients averse to injections. Safety profiles from phase 3 trials show similar tolerability to injectables, though monitoring for dehydration and GI effects remains key.

Broad Economic Impact: Jobs, Taxes, and Regional Growth

The Goodbody Economic Report was unveiled at the annual conference of the Irish Pharmaceutical Healthcare Association (IPHA) at the Dublin Royal Convention Centre. It estimates that 75,000 workers are employed directly and indirectly in Ireland in pharma and related activities, with sectoral employment growing three times faster than the wider labour market. The industry paid an estimated €6bn in total taxes in 2023, including 18% of all corporation tax receipts.

Ireland (€100bn) was Europe's second-largest exporter of pharmaceuticals behind Germany (€115bn) in 2024, ahead of third-ranked Belgium (€79bn). Ireland has the highest number of FDA-approved manufacturing sites per capita in Europe. The report highlights the sector's role in regional development, concentrated in the South-East and South-West, driving vital investment, employment, and economic growth.

IPHA's Vision: From Economic Strength to Patient Access

"Today's Goodbody report shows just how important our sector has become, not just for Ireland, but for Europe, and for global healthcare. The challenge now is to ensure patients can access innovation as quickly as we deliver it," said IPHA president Shane Ryan.

Meanwhile, the IPHA noted a new framework agreement agreed in January will deliver faster access to innovative and life-changing medicines for Irish patients. IPHA chief executive Oliver O'Connor emphasized: "The new IPHA Framework Agreement marks a decisive shift towards a system that values innovation and ensures patients in Ireland can access breakthrough medicines faster. With Ireland soon taking up the EU Presidency, we have a major opportunity to lead Europe toward a more competitive, innovation-friendly, and patient-focused future."

This agreement could accelerate approvals for drugs like tirzepatide and future GLP-1s, reducing wait times for metabolic health patients.

Key Takeaways: What This Means for Patients and the Economy

• Export Milestone: Pharma now 53% of Irish goods exports, with weight-loss drugs contributing 20% via GLP-1 APIs.
• Eli Lilly's Role: Facilities in Kinsale and Limerick support global tirzepatide production; $9bn Indiana investment incoming.
• Innovation Ahead: Orforglipron oral GLP-1 could launch Q2 2025 in the US.
• Jobs and Taxes: 75,000 employed; €6bn taxes in 2023.
• Patient Focus: New IPHA framework promises quicker access to metabolic therapies.

Conclusion: A Bright Future for GLP-1 Manufacturing and Access

The Eli Lilly-led boom in weight-loss pharma exports from Ireland not only bolsters the economy but also paves the way for broader patient access to transformative GLP-1 treatments. As demand grows, maintaining high standards in manufacturing will be key. Patients interested in Ozempic, Wegovy, Mounjaro, or Zepbound should consult providers for personalized guidance, weighing benefits against side effects like those tracked via apps such as Shotlee. This story of economic vitality intertwined with health innovation offers optimism for metabolic health worldwide.